<DOC>
	<DOCNO>NCT02293031</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy gene-activated matrix ( `` Nucleostim '' ) regeneration bone tissue maxillofacial area . Patients congenital acquire maxillofacial defect ( socket extract teeth , bone defect injury , surgery , excision benign neoplasms pseudotumors , etc . ) alveolar bone atrophy include study .</brief_summary>
	<brief_title>Gene-activated Matrix Bone Tissue Repair Maxillofacial Surgery</brief_title>
	<detailed_description>All patient enrol study receive standard surgery procedure indicate accordance medical care standard certain disease . Maxillofacial bone defect ( form injury , surgery , excision benign neoplasms pseudotumors , teeth extraction , etc . ) area alveolar bone atrophy fill gene-activated matrix `` Nucleostim '' . Safety efficacy implant osteoplastic material assess physical examination , comprehensive laboratory test , X-ray examination within 60 day operation .</detailed_description>
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Bone Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Alveolar Bone Loss</mesh_term>
	<mesh_term>Tooth Diseases</mesh_term>
	<mesh_term>Jaw Fractures</mesh_term>
	<criteria>obtain voluntary informed consent participation clinical study ; congenital acquire maxillofacial bone defect ( socket extract teeth , bone defect injury , surgery , excision benign neoplasms pseudotumors , etc . ) alveolar bone atrophy . able unwilling give voluntary inform consent study follow requirement clinical study ; decompensated chronic visceral disease ; clinically significant laboratory abnormality ; HIV , HBV HCV antibodies serum ; alcohol consumption within 4 day prior study ; history drug addiction ; participation clinical study ( administration study product ) within 3 month prior study ; condition limit study compliance ( dementia , psychoneurological disease , drug addiction , alcoholism , etc . ) ; malignancy include postsurgical period chemo ( ) radiation therapy ) ; vascular malformation ; pregnancy lactation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>maxillofacial bone defect</keyword>
	<keyword>alveolar ridge atrophy</keyword>
	<keyword>gene-activated matrix</keyword>
	<keyword>VEGF gene</keyword>
	<keyword>DNA plasmid</keyword>
	<keyword>bone gene therapy</keyword>
</DOC>